Skip to main content

Philadelphia cell and gene therapy firm emerges from stealth mode with $64M in funding, Navy Yard space

A Philadelphia cell and gene therapy contract manufacturer is emerging from stealth mode with $64 million in funding, a custom-built facility at the Navy Yard and a veteran health care executive as its new CEO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.